Aclaris' treatment for common skin condition gets FDA OK

It's good news from the FDA for Alcaris Therapeutics and the more 83 million adults in the United States people who suffer from certain types of non-cancerous skin growths. Malvern-based Alcaris' Eskata, a topical non-invasive treatment for rasied seborrheric keratoses, or SKs, was approved by the Food and Drug Administration. You might not have heard of SKs, but Aclaris says the condition is more common than the better-known skin ailments acne, psoriasis and rosacea combined. “This achievement…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news